bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

helpersCheckIsPostiesArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

moreOnThisArticles

urlAlias

commentCount

sponsorType

authorLocations

authors

paywallTypes

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

socialHeadline

headline

flag

firstTopic

glossary

flattenTypeIds

publishedDate

additionalInfoBoxes

images

image

relatedLinks

relatedNewsletters

__typename

createdDate

sponsor

factSheets

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

copyrighted

customTimezone

liveContents

Andrew Barclay

This article originally appeared on ABACUS
Chinese consumers will soon be able to access WebMD’s health content after it signed a content-licensing deal with Tencent -- meaning close to one billion people will be able to search what their aches and pain might mean.
The deal will cover articles, videos and slideshows and will focus on illnesses that are more relevant to Chinese people, according to the Wall Street Journal.
One of those is lung cancer, which has seen a sharp increase in cases over the past 10-15 years.
For WebMD the move makes sense: The Chinese pharmaceutical market is already the second largest in the world and is projected to be worth $1.6 trillion by 2020.
China’s ‘Facebook for plastic surgery’ lets users speak to doctors and even pay for procedures on the site 
But for Tencent’s part, it’s an interesting choice of partner -- largely because of WebMD’s somewhat dubious reputation in the West.
A 2015 study from the British Medical Journal found the chances of getting the right diagnosis from WebMD or similar sites was largely “hit or miss”.
There are also concerns over its ties to pharmaceutical companies, who pay for ads to appear on the site. As the New York Times recently put it: “WebMD has become permeated with pseudomedicine and subtle misinformation.”
The content is expected to be rolled out by the end of the year.

For more insights into China tech, sign up for our tech newsletters, subscribe to our Inside China Tech podcast, and download the comprehensive 2019 China Internet Report. Also roam China Tech City, an award-winning interactive digital map at our sister site Abacus.



Tencent beats estimates with 47% profit jump, driven by video gaming

China’s Zhipu AI says its app can operate your smartphone for you

Hong Kong’s civil servants get the app safety message

Ant CEO Eric Jing touts tokenisation benefits for cross-border transactions at FinTech Week

WebMD deal means the doctor is in... WeChat

Tencent will adapt WebMD content focusing on illnesses more common in China

China’s ‘Facebook for plastic surgery’ lets users speak to doctors and even pay for procedures on the site